Advanced in Alveolar Soft Part Sarcoma

Dr. Mark W. Karwal

Hematology Oncology | Oncology | Hematology
State University Of Iowa
200 Hawkins Dr, 
Iowa City, IA 
Accepting New Patients
Advanced in Alveolar Soft Part Sarcoma
State University Of Iowa
200 Hawkins Dr, 
Iowa City, IA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Karwal is a Hematologist Oncology specialist and an Oncologist in Iowa City, Iowa. Dr. Karwal is rated as an Advanced provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Angiosarcoma, Breast Cancer, Inflammatory Breast Cancer, and Fibrolamellar Carcinoma. Dr. Karwal is currently accepting new patients.

His clinical research consists of co-authoring 9 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in IA
Hospital Affiliations
University Of Iowa Health Care Medical Center Down
University Of Iowa Hospital & Clinics
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
Sanford Health
  • HMO
  • PPO
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 18 Less Insurance Carriers -

Locations

STATE UNIVERSITY OF IOWA
200 Hawkins Dr, Iowa City, IA 52242

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib
Enrollment Status: Completed
Publish Date: January 20, 2023
Intervention Type: Drug
Study Drug: Ramucirumab
Study Phase: Phase 3
2017-01: Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma
2017-01: Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma
Enrollment Status: Completed
Publish Date: August 06, 2020
Intervention Type: Other
View 5 Less Clinical Trials

9 Total Publications

Hyperammonemic Encephalopathy in Fibrolamellar Hepatocellular Carcinoma: A Case of Rapid Neurologic Recovery Following Cytoreductive Surgery.
Hyperammonemic Encephalopathy in Fibrolamellar Hepatocellular Carcinoma: A Case of Rapid Neurologic Recovery Following Cytoreductive Surgery.
Journal: Journal of clinical and experimental hepatology
Published: April 15, 2025
Similar Doctors
Elite in Alveolar Soft Part Sarcoma
Dr. Mohammed M. Milhem
Hematology Oncology | Hematology | Oncology
Elite in Alveolar Soft Part Sarcoma
Dr. Mohammed M. Milhem
Hematology Oncology | Hematology | Oncology

State University Of Iowa

200 Hawkins Dr, 
Iowa City, IA 
 (0.1 miles away)
319-356-1616
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mohammed Milhem is a Hematologist Oncology specialist and a Hematologist in Iowa City, Iowa. Dr. Milhem is rated as an Elite provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Melanoma, Adult Soft Tissue Sarcoma, Fibrosarcoma, and Alveolar Soft Part Sarcoma. Dr. Milhem is currently accepting new patients.

Experienced in Alveolar Soft Part Sarcoma
Dr. John M. Rieth
Hematology | Oncology
Experienced in Alveolar Soft Part Sarcoma
Dr. John M. Rieth
Hematology | Oncology

State University Of Iowa

200 Hawkins Dr, 
Iowa City, IA 
 (0.1 miles away)
319-356-1616
Languages Spoken:
English
See accepted insurances
Offers Telehealth

John Rieth is a Hematologist and an Oncologist in Iowa City, Iowa. Dr. Rieth is rated as an Experienced provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Alveolar Soft Part Sarcoma, Undifferentiated Pleomorphic Sarcoma, and Mesenchymoma.

Experienced in Alveolar Soft Part Sarcoma
Dr. Christian Schultheis
Hematology | Oncology
Experienced in Alveolar Soft Part Sarcoma
Dr. Christian Schultheis
Hematology | Oncology

State University Of Iowa

200 Hawkins Dr, 
Iowa City, IA 
 (0.1 miles away)
319-356-1616
Languages Spoken:
English
See accepted insurances

Christian Schultheis is a Hematologist and an Oncologist in Iowa City, Iowa. Dr. Schultheis is rated as a Distinguished provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Familial Pancreatic Cancer, Familial Colorectal Cancer, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Karwal's expertise for a condition
ConditionClose
    View All 24 Advanced Conditions
    View All 55 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile